Edition:
United Kingdom

Constellation Pharmaceuticals Inc (CNST.OQ)

CNST.OQ on NASDAQ Stock Exchange Global Select Market

6.75USD
17 Oct 2018
Change (% chg)

$-0.13 (-1.89%)
Prev Close
$6.88
Open
$6.88
Day's High
$6.89
Day's Low
$6.71
Volume
3,109
Avg. Vol
--
52-wk High
$12.21
52-wk Low
$6.42

Summary

Name Age Since Current Position

Mark Goldsmith

Executive Chairman , Venture Partner

Keith Dionne

President, Chief Executive Officer, Director

Matthias Jaffe

Chief Financial Officer

James Audia

Chief Scientific Officer

Brenda Sousa

2010 Vice President - Human Resources

Michael Cooper

Chief Medical Officer

Steven Hoerter

47 2018 Independent Director

Elizabeth Trehu

58 2018 Independent Director

Biographies

Name Description

Mark Goldsmith

Dr. Mark A. Goldsmith, M.D. Ph.D. is the Executive Chairman, Venture Partner of Constellation Pharmaceuticals, Inc. He is also the Venture Partner at Third Rock Ventures. Prior to this, he served as President and Chief Executive Officer of Constellation from 2009 to 2012. He previously held senior executive positions in the biotechnology industry, including Senior Executive-in-Residence at Prospect Venture Partners, Chief Executive Officer of Cogentus Pharmaceuticals and Senior Vice President of Genencor International. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital, and was a Consultant to pharmaceutical and biotechnology companies.

Keith Dionne

Dr. Keith E. Dionne, Ph.D. is the President, Chief Executive Officer and Director of Constellation Pharmaceuticals, Inc. Previously, he served as CEO of Surface Logix, Inc. and as President and CEO of Alantos Pharmaceuticals, leading the company's acquisition by Amgen in July 2007. Prior to joining Alantos, Dr. Dionne was with Millennium Pharmaceuticals, Inc., where he held positions of increasing responsibility, concluding his seven-year tenure as both Vice President of Research and Development Strategy and Vice President and General Manager, Technology Business. Before his tenure with Millennium, Dr. Dionne served as Head of Preclinical Research & Development, implants at ALZA Pharmaceuticals. Dr. Dionne began his career in biotechnology as one of four original scientists at CytoTherapeutics, Inc. He has served as an Adjunct Professor in the Biomedical Department at Brown University and received both a Ph.D. in chemical engineering and M.S. in the program for technology policy from Massachusetts Institute of Technology..

Matthias Jaffe

Mr. Matthias B. Jaffe is the Chief Financial Officer of the Company. Previously, Mr. Jaffe joined Constellation in April 2012 bringing over 12 years of experience in corporate finance and strategic management to his role. Previously, Mr. Jaffe served as CFO and VP of Business Development at Zafgen, a Third Rock Ventures’ portfolio company. He has also held senior positions in a number of private, venture-backed companies in the life science and cleantech space, including Alantos Pharmaceuticals, which under the leadership of Dr. Dionne, was acquired by Amgen in 2007. Prior to Alantos, Mr. Jaffe was a principal at Earlybird Venture Capital (Munich, Germany), where he supported new investments activities and existing portfolio companies. He also worked at the Boston Consulting Group, where he was a member of the pharmaceutical practice group, assisting Fortune 500 companies with strategic management issues. Mr. Jaffe holds a M.S. in molecular biology from the Massachusetts Institute of Technology, an MBA from INSEAD (Fontainebleau, France).

James Audia

Dr. James E. Audia, Ph.D., is the Chief Scientific Officer at Constellation Pharmaceuticals, Inc. Dr. Jim Audia joined Constellation in January 2011 following a highly productive career in drug discovery at Eli Lilly and Company. Dr. Audia held several key leadership roles during his 23-year tenure at Lilly. As a Distinguished Lilly Scholar, the highest level of the company’s scientific ladder, he made seminal technical and strategic contributions to the Lilly drug pipeline. Prior to this role, Dr. Audia was Executive Director, Discovery Chemistry Research and Technologies, where he had global responsibility for delivery of small molecule drug candidates across all therapeutic areas. He also played a major role in companywide leadership of product strategy and portfolio management for Lilly for more than a decade. Over the course of his career, Dr. Audia’s scientific work has contributed to more than 12 development candidates, including transformative contributions to the treatment of Alzheimer’s disease through his discovery of both the first gamma secretase inhibitor and an industry-leading beta secretase inhibitor. Dr. Audia is a named inventor on more than 90 issued US patents and has published and presented extensively. He received his Ph.D. in Organic Chemistry from the University of South Carolina and did postdoctoral training at Yale University before joining Lilly.

Brenda Sousa

Ms. Brenda Sousa is the Vice President - Human Resources at Constellation Pharmaceuticals, Inc. Prior to joining Constellation Ms. Sousa was the Vice President of Human Resources and Operations at EPIX Pharmaceuticals, where she served as a member of the global executive management team and focused on the development and implementation of business strategy, operations, and organizational development for US companies with international offices. Before joining EPIX, she was Director of Human Resources for RKS Health Ventures and Spence Center for Women’s Health, a start-up venture that was ultimately purchased by Partners Healthcare. Prior to her human resources career, Ms. Sousa worked in the hospitality industry focusing on sales and marketing. Brenda joined the Board of Career Collaborative in 2004 where she initiated and served as Chair of the Employer Advisory Board. Brenda holds a Bachelor of Arts Degree from the University of Massachusetts.

Michael Cooper

Dr. Michael R. Cooper M.D. is the Chief Medical Officer at Constellation Pharmaceuticals, Inc. Before joining Constellation Dr. Cooper held leadership positions at Novartis Pharmaceuticals, where he was Clinical Head of Oncology Translational Medicine in Cambridge, Massachusetts, and at Millennium Pharmaceuticals, where he was Vice President of Oncology Clinical Development. Before joining the pharmaceutical industry, Dr. Cooper practiced medical oncology and hematology in various academic institutions, where he led programs in the early clinical development of novel anti-cancer compounds. His interest in cancer pharmacology, pharmacokinetics and biomarker development was developed during his tenure as a Senior Clinical Investigator in the Clinical Pharmacology and Medicine Branches of the National Cancer Institute in Bethesda, Maryland. Dr. Cooper received his M.D. from Duke University School of Medicine, which is also where he completed his residency in internal medicine and his fellowship in hematology and medical oncology.

Steven Hoerter

Mr. Steven L. Hoerter is Independent Director of the Company. He has served as the chief commercial officer of Agios Pharmaceuticals, a biopharmaceutical company, since February 2016. He has more than 20 years of global pharmaceutical and biotechnology experience, most recently having served, from August 2011 to February 2016, as executive vice president and chief commercial officer at Clovis Oncology, Inc., a biopharmaceutical company. There, Mr. Hoerter built and led the global commercial organization that developed go-to-market strategies for two oncology therapies. Before joining Clovis in August 2011, he was general manager and management center head at Roche Group for the Sub-Saharan Africa and Indian Ocean Region. From 2005 to 2010, Mr. Hoerter held a variety of positions at Genentech, Inc., including serving on the senior leadership team for Genentech’s bio-oncology business as senior director, pipeline development and commercial operations. Prior to that, Mr. Hoerter held commercial roles at Chiron Corporation and Eli Lilly and Company in the United States, Europe and Africa. Mr. Hoerter received his B.A. from Bucknell University, M.B.A. from Tilburg University and M.S. in management from Purdue University.

Elizabeth Trehu

Dr. Elizabeth G. Trehu, M.D. is Independent Director of the Company. She has served as the chief medical officer of Jounce Therapeutics, Inc., a clinical stage immunotherapy company, since November 2015. Prior to joining Jounce, Dr. Trehu served as the chief medical officer of Promedior, Inc., a biotechnology company, from 2012 to November 2015. Previously, Dr. Trehu served as vice president, product development and medical affairs for Infinity Pharmaceuticals, Inc. from 2010 to 2012. Earlier in her career, Dr. Trehu served in a variety of roles for Genzyme Corporation, including as the vice president and general manager, hematology from 2009 to 2010, vice president and general manager of Clolar from 2008 to 2009 and vice president, global medical affairs of Genzyme Oncology from 2006 to 2008. From 2002 to 2006, Dr. Trehu served in a variety of positions at Millennium Pharmaceuticals, Inc., including as vice president of oncology global medical affairs in 2006. Dr. Trehu holds an M.D. from the New York University School of Medicine and an A.B. in English from Princeton University.